Development of medications for alcohol use disorders: recent advances and ongoing challenges
- 10 May 2005
- journal article
- review article
- Published by Taylor & Francis in Emerging Drugs
- Vol. 10 (2) , 323-343
- https://doi.org/10.1517/14728214.10.2.323
Abstract
During the past decade, efforts to develop medications for alcoholism have burgeoned. Three agents, disulfiram, naltrexone and acamprosate, are now approved in a large number of countries. Although many patients have benefited from existing medications, their effects are moderate, and some alcoholics fail to respond to them. A host of new agents are currently under active investigation. Critical barriers must be overcome to ensure that future efforts in the development of medications for alcohol use disorders reach full fruition. These challenges include: establishing key targets for drug discovery; validating animal and human screening models; and developing biomarkers to help predict treatment success. In addition, it is important to formulate methodological and statistical strategies to efficiently conduct alcohol pharmacotherapy trials; to specify genetic and phenotypic patient characteristics associated with efficacy and safety for lead compounds; to forge productive alliances among governmental agen...Keywords
This publication has 174 references indexed in Scilit:
- The mGluR5 Antagonist 6-Methyl-2-(phenylethynyl)pyridine Decreases Ethanol Consumption via a Protein Kinase Cϵ-Dependent MechanismMolecular Pharmacology, 2005
- The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002Drug and Alcohol Dependence, 2004
- The Efficacy of Acamprosate in the Maintenance of Abstinence in Alcohol‐Dependent Individuals: Results of a Meta‐AnalysisAlcohol, Clinical and Experimental Research, 2004
- Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphismPsychiatric Genetics, 2003
- Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overviewProstaglandins, Leukotrienes & Essential Fatty Acids, 2002
- Naltrexone in the Treatment of Alcohol DependenceNew England Journal of Medicine, 2001
- Reduced operant ethanol self‐administration and in vivo mesolimbic dopamine responses to ethanol inPKCε‐deficient miceEuropean Journal of Neuroscience, 2000
- Naltrexone Alters Subjective and Psychomotor Responses to Alcohol in Heavy Drinking SubjectsNeuropsychopharmacology, 2000
- Interaction between the Functional Polymorphisms of the Alcohol-Metabolism Genes in Protection against AlcoholismAmerican Journal of Human Genetics, 1999
- A Double‐Blind, Placebo‐Controlled Pilot Study to Evaluate the Efficacy and Safety of Oral Nalmefene HCI for Alcohol DependenceAlcohol, Clinical and Experimental Research, 1994